Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00178295 · ClinicalTrials.gov registry record
Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury
A clinical trial of Brain Neoplasm, sponsored by University of Rochester.
- Completed
- Registry status
- 44
- Enrollment target
- 1
- Study location
NCT00178295 is a study of Brain Neoplasm that has completed, run by University of Rochester. The registered enrollment target is 44 participants, below the 49-participant average among 9 other Brain Neoplasm trials with a reported enrollment target (10% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00178295, a study of Brain Neoplasm, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
Treatment for brain cancer may include radiation therapy. Radiation therapy is the treatment of tumors with X-rays. This study is related to understanding the side effects of radiation treatment for brain tumors. This study is being conducted by the University of Rochester Cancer Center to compare the extent of side effects of brain cancer treatment with changes in levels of blood proteins called cytokines.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
Study Locations (1)
New York
- University of Rochester, Dept. Radiation Oncology - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 1999-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00178295
The ClinicalTrials.gov registry entry for NCT00178295 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 49-participant average among 9 other Brain Neoplasm trials with a reported enrollment target (10% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT00178295 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00178295 about?
NCT00178295 is a clinical study titled "Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury". Treatment for brain cancer may include radiation therapy. Radiation therapy is the treatment of tumors with X-rays. This study is related to understanding the side effects of radiation treatment for brain tumors. This study is being conducted by the University of Rochester Cancer Center to compare ...
What is the current status of trial NCT00178295?
This trial is currently completed. The enrollment target is 44 participants. The study started on 1999-11.
What conditions does trial NCT00178295 study?
This clinical trial studies the following conditions: Brain Neoplasm.
What interventions are being tested in trial NCT00178295?
The interventions under investigation include: Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT00178295?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00178295 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
Tumor Related Epilepsy
RECRUITING
-
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RECRUITING · Phase 2
-
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
RECRUITING · NA
-
Navigated Repetitive Transcranial Magnetic Stimulation in Improving Motor Rehabilitation in Participants With Brain Tumors
ACTIVE NOT RECRUITING · NA
-
MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.